This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexion Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Alexion Pharmaceuticals, Inc. (ALXN)

Q2 2012 Earnings Call

July 25, 2012 10:00 AM ET

Executives



Lenny Bell – CEO

Tom Dubin – SVP and Chief Legal Officer

Vikas Sinha – SVP and CFO

David Hallal – SVP, Global Commercial Operations

Steve Squinto – EVP and Head of Research and Development

Analysts



Geoff Meacham – JP Morgan

Rachel McMinn – Bank of America/Merrill Lynch

Eric Schmidt – Cowen & Company

David Friedman – Morgan Stanley

Shane – Wells Fargo

Salveen Richter – Canaccord

Geoffrey Porges – Bernstein

Navdeep Singh – Deutsche Bank

Ying Huang – Barclays

Ian Somaiya – Piper Jaffray

Matt Roden – UBS

Howard Liang – Leerink Swann

Chris Raymond – Robert Baird

Presentation



Operator

Good day, ladies and gentlemen, and welcome to the Second Quarter 2012 Alexion Pharmaceuticals Earnings Conference Call.

(Operator Instructions)

I would now like to turn the presentation over to your host for today, Dr. Bell. Please proceed, sir.

Lenny Bell

Thank you, operator, and good morning. Thank you for joining us on today’s call to discuss Alexion’s performance for the second quarter of 2012.

With me on the call this morning are members of Alexion management: Steve Squinto, Executive Vice President and Head of R&D; Vikas Sinha, Senior Vice President and Chief Financial Officer; David Hallal, Senior Vice President, Global Commercial Operations; and Tom Dubin, Senior Vice President and Chief Legal Officer. We also welcome our entire Alexion team working around the world.

Vikas, David and Steve will join me on today’s call to report on our progress in the second quarter, and to provide an update on our outlook for the second half of this year.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs